BR0215254A - Composições e métodos para intensificar a liberação de corticoesteróides - Google Patents

Composições e métodos para intensificar a liberação de corticoesteróides

Info

Publication number
BR0215254A
BR0215254A BR0215254-1A BR0215254A BR0215254A BR 0215254 A BR0215254 A BR 0215254A BR 0215254 A BR0215254 A BR 0215254A BR 0215254 A BR0215254 A BR 0215254A
Authority
BR
Brazil
Prior art keywords
compositions
methods
penetration enhancers
corticosteroid release
enhancing
Prior art date
Application number
BR0215254-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Eugene H Gans
Mitchell S Wortzman
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21893928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0215254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of BR0215254A publication Critical patent/BR0215254A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C16/00—Erasable programmable read-only memories
    • G11C16/02—Erasable programmable read-only memories electrically programmable
    • G11C16/04—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS
    • G11C16/0408—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS comprising cells containing floating gate transistors
    • G11C16/0433—Erasable programmable read-only memories electrically programmable using variable threshold transistors, e.g. FAMOS comprising cells containing floating gate transistors comprising cells containing a single floating gate transistor and one or more separate select transistors
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2216/00—Indexing scheme relating to G11C16/00 and subgroups, for features not directly covered by these groups
    • G11C2216/02—Structural aspects of erasable programmable read-only memories
    • G11C2216/10—Floating gate memory cells with a single polysilicon layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR0215254-1A 2001-12-21 2002-12-12 Composições e métodos para intensificar a liberação de corticoesteróides BR0215254A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/037,360 US6765001B2 (en) 2001-12-21 2001-12-21 Compositions and methods for enhancing corticosteroid delivery
PCT/US2002/039882 WO2003055445A2 (en) 2001-12-21 2002-12-12 Compositions and methods for enhancing corticosteriod delivery

Publications (1)

Publication Number Publication Date
BR0215254A true BR0215254A (pt) 2005-02-01

Family

ID=21893928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215254-1A BR0215254A (pt) 2001-12-21 2002-12-12 Composições e métodos para intensificar a liberação de corticoesteróides

Country Status (9)

Country Link
US (8) US6765001B2 (enExample)
EP (2) EP2363150A1 (enExample)
JP (2) JP2005524614A (enExample)
CN (1) CN1617730A (enExample)
BR (1) BR0215254A (enExample)
CA (1) CA2471041C (enExample)
IL (1) IL162581A0 (enExample)
MX (1) MXPA04006014A (enExample)
WO (1) WO2003055445A2 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630152B2 (en) * 1999-04-07 2003-10-07 Shen Wei (Usa), Inc. Aloe vera glove and manufacturing method
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
ES2532906T5 (es) 2002-10-25 2022-03-23 Foamix Pharmaceuticals Ltd Espuma cosmética y farmacéutica
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7575739B2 (en) * 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
US7897587B2 (en) 2004-09-03 2011-03-01 Nycomed Us Inc. Topical dermatological formulations and use thereof
CA2609953A1 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2007046315A1 (ja) * 2005-10-17 2007-04-26 Nisshin Kyorin Pharmaceutical Co., Ltd. 皮膚外用剤
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP1957080A4 (en) * 2005-12-09 2013-10-09 Fougera Pharmaceuticals Inc TOPICAL GLUCOCORTICOSTEROID FORMULATIONS
US20070179121A1 (en) * 2006-02-02 2007-08-02 Plott R T Method of treating pediatric patients with corticosteroids
WO2007103555A2 (en) * 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
FR2898499B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US8413435B2 (en) * 2006-06-13 2013-04-09 Wescast Industries, Inc. Exhaust manifolds including heat shield assemblies
PL2494959T3 (pl) * 2006-07-05 2015-06-30 Foamix Pharmaceuticals Ltd Nośnik ze spienialnego kwasu dikarboksylowego oraz kompozycje farmaceutyczne z nośnikiem
GB2443162B (en) * 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
GB2443161B (en) * 2006-10-28 2011-03-23 Nupharm Lab Ltd Clobetasol spray
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
WO2008083149A1 (en) * 2006-12-27 2008-07-10 Abeille Pharmaceuticals Inc. Transdermal method and patch for corticosteroid administration
US20100210932A1 (en) * 2007-03-20 2010-08-19 Bayer Healthcare Llc Method of analyzing an analyte
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20090298803A1 (en) * 2008-05-28 2009-12-03 Glenmark Generics Ltd. Pharmaceutical composition comprising fluocinonide
KR20160130519A (ko) * 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
TW201035054A (en) * 2009-02-27 2010-10-01 Lundbeck & Co As H Methods of administering (4aR, 10aR)-1-n-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and pharmaceutical compositions thereof
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
AR077490A1 (es) * 2009-07-21 2011-08-31 Novartis Ag Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011026076A2 (en) 2009-08-31 2011-03-03 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
WO2011039637A2 (en) 2009-10-02 2011-04-07 Foamix Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
EP2667860A1 (en) * 2011-01-24 2013-12-04 Anterios, Inc. Compositions of empty nanoparticles and their use for treating dermatological conditions
GB201110632D0 (en) * 2011-06-22 2011-08-03 King S College London Drug delivery formulations
JP5820206B2 (ja) * 2011-09-13 2015-11-24 日東電工株式会社 経皮吸収促進用組成物および貼付製剤
US20140112959A1 (en) * 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
AU2014305778B2 (en) 2013-08-08 2019-11-21 Ligand Pharmaceuticals Incorporated Topical compositions and methods of using the same
AU2014305760B2 (en) * 2013-08-09 2017-06-08 Puretech Scientific Llc Skin care compositions having cyclic diesters and methods thereof
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
EP3143986A1 (en) * 2015-09-21 2017-03-22 Zimmer MedizinSysteme GmbH Hydrophilic gel for topical delivery of 5-aminolevulinic acid and production thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
JP2021534161A (ja) * 2018-08-16 2021-12-09 ドクター・レディーズ・ラボラトリーズ・リミテッド 局所用油性組成物
CN113543827B (zh) * 2019-02-27 2025-01-21 奥蒂卡拉股份有限公司 用于治疗鼻、鼻腔鼻窦和鼻咽组织感染和/或炎症的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4017615A (en) 1970-10-29 1977-04-12 Syntex Corporation Propylene carbonate ointment vehicle
US3934013A (en) * 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition
EP0020794B1 (en) * 1979-06-08 1983-01-12 Toko Yakuhin Kogyo Kabushiki Kaisha Creamy preparation containing steroid and process for the preparation thereof
JPS58225009A (ja) * 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
JPS6136219A (ja) * 1984-07-27 1986-02-20 Shiseido Co Ltd 皮膚外用剤
US4879119A (en) * 1984-02-21 1989-11-07 Yamanouchi Pharmaceutical Co., Ltd. Patch
US4831023A (en) 1986-06-27 1989-05-16 Thames Pharmacal Co., Inc. Water washable vehicles for topical use
JPH0676328B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5422361A (en) * 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
JP3655305B2 (ja) * 1992-11-23 2005-06-02 エスティー ローダー インコーポレーテッド 自己日焼け化粧料組成物及びそれを使用する方法
US6300326B1 (en) 1994-11-02 2001-10-09 Michael R. Dobbs Composition and method for control and treatment of cutaneous inflammation
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
JPH10204001A (ja) * 1996-11-15 1998-08-04 Kao Corp 経皮吸収促進剤
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
JPH11158060A (ja) * 1997-11-18 1999-06-15 Bristol Myers Squibb Co 長期間貯蔵される組成物中の医薬及び／又は透過増強剤が不安定なときに透過増強剤により医薬の皮膚透過を増強させる方法及び組成物
US6066281A (en) * 1998-06-16 2000-05-23 Velcro Industries B.V. Fastener products and their production
WO2000040250A1 (fr) * 1999-01-06 2000-07-13 Taisho Pharmaceutical Co.,Ltd. Lotion a base d'amelometasone
US6656928B1 (en) * 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Also Published As

Publication number Publication date
US20030186951A1 (en) 2003-10-02
EP1465636A2 (en) 2004-10-13
US20070142344A1 (en) 2007-06-21
US20120289490A1 (en) 2012-11-15
CA2471041C (en) 2012-07-03
US20030130247A1 (en) 2003-07-10
WO2003055445A3 (en) 2003-10-09
AU2002360589A1 (en) 2003-07-15
US6765001B2 (en) 2004-07-20
AU2002360589B2 (en) 2007-03-15
US20100210609A2 (en) 2010-08-19
US20100210614A2 (en) 2010-08-19
US20070142343A1 (en) 2007-06-21
WO2003055445A2 (en) 2003-07-10
US20030176408A1 (en) 2003-09-18
US7794738B2 (en) 2010-09-14
EP1465636A4 (en) 2006-04-05
IL162581A0 (en) 2005-11-20
JP2010280689A (ja) 2010-12-16
US7220424B2 (en) 2007-05-22
CN1617730A (zh) 2005-05-18
US20100210615A2 (en) 2010-08-19
JP2005524614A (ja) 2005-08-18
US20040198709A1 (en) 2004-10-07
US7771733B2 (en) 2010-08-10
EP2363150A1 (en) 2011-09-07
US20090176750A1 (en) 2009-07-09
CA2471041A1 (en) 2003-07-10
US7217422B2 (en) 2007-05-15
US8232264B2 (en) 2012-07-31
MXPA04006014A (es) 2005-07-13

Similar Documents

Publication Publication Date Title
BR0215254A (pt) Composições e métodos para intensificar a liberação de corticoesteróides
BRPI0409348B8 (pt) formulações para tratamento de rinossinusite induzida por fungo em um mamífero
BR0204115A (pt) Utilização de um copolìmero anfìfilo, processo de preparação de uma dispersão de um composto orgânico insolúvel, dispersão e composição cosmética de uso tópico
CY1110085T1 (el) Μεθοδος θεραπειας της δυσλειτουργιας στυσης και αυξησης της λιμπιντο στους ανδρες
CR20220547A (es) Compuestos de 2,4-dioxopirimidina inhibidores de cd73
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
TW200616650A (en) Semi-solid delivery vehicle and pharmaceutical compositions
BR0311764A (pt) Composição herbicida
DK1887016T3 (da) Fragmenter af humant choriongonadotropin (HCG) som immunoregulator
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BR9916076A (pt) Composição adequada para aplicação tópica, uso de uma composição tópica métodos para melhorar o distúrbio do estìmulo sexual feminino, e para intensificar o estìmulo sexual feminino, e a resposta sexual feminina, artigo de manufatura
CY1111100T1 (el) Καλλυντικη συνθεση για τη θεραπεια γηρασμενου και/ή στρεσαρισμενου δερματος
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0309606A (pt) Hidrolisados de mercaptosilano bloqueado como agentes de acoplamento para composições elastoméricas carregadas com minerais
BR9909329A (pt) Método para estabilizar composições farmacêuticas pelo uso especial de um antioxidante
BR0113649A (pt) Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
BRPI0516059A (pt) pelìcula proterora de piso, método para aplicar uma pelìcula ao piso, e, piso
BRPI0412971A (pt) método de alongamento do cabelo
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BR0115952A (pt) Composição de emulsão para administração terapêutica, método de administração, processo para o preparo de uma formulação contendo derivados de fosfato de agentes de transferência de elétrons
BRPI0417672A (pt) processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
BR0305412A (pt) Composição de tratamento de superfìcie para substratos macios
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии
BR0207365A (pt) Composição, composição não-sólida, método para conferir estabilidade fìsica, método para maquilagem, cuidado ou tratamento e kit de multicompartimentos
BR0303912A (pt) Composição para o condicionamento, composição para o condicionamento durável, método para o condicionamento, método para o condicionamento durável, método para o cuidado ou tratamento e kit para o cuidado, tratamento, condicionamento ou condicionamento durável

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: MEDICIS PHARMACEUTICAL CORPORATION (US)

Free format text: SEDE ALTERADA CONFORME PET NO 20080153304-RJ DE 12.12.2008

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/56; A61P 17/00; A61P 17/04

Ipc: A61K 31/56 (2011.01), A61P 17/00 (2011.01), A61P 1

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.